DNTH: Advancing neuromuscular pipeline with strong clinical data, key catalysts ahead, and robust cash runway
Significant pipeline progress was highlighted, with positive clinical data for claseprubart in MG and CIDP, and key MMN results expected soon. The company is well-positioned in competitive neuromuscular markets, advancing early-stage assets, and has a strong cash runway into 2030.Based on Dianthus…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.